Related Experiment Videos

Do we need placebos to evaluate new drugs in children with schizophrenia?

Jorge L Armenteros1, Ashraf G Mikhail

  • 1University of Miami School of Medicine, Division of Child and Adolescent Psychiatry, Department of Psychiatry (D29), P.O. Box 016960, Miami, FL 33101, USA.

Psychopharmacology
|February 28, 2002
PubMed

Insights

Placebo-controlled studies are ethically justified and scientifically necessary for developing new treatments for childhood schizophrenia. This research ensures children receive safe and effective medication by using placebo controls.

Area of Science:

  • Pediatric Psychiatry
  • Clinical Pharmacology
  • Medical Ethics

Background:

  • Ethical considerations arise with placebo use in human research.
  • These concerns are heightened when studying vulnerable populations like children, particularly those with schizophrenia.

Purpose of the Study:

  • Critically review current ethical and scientific issues surrounding placebo use in pediatric schizophrenia research.
  • Provide original insights into the ethical application of placebos in this population.

Main Methods:

  • Conducted a manual literature review.
  • Examined relevant agency policies.
  • Synthesized findings to present original ethical considerations.

Main Results:

  • Identified compelling scientific and ethical justifications for placebo-controlled studies in childhood schizophrenia.
  • Demonstrated the need and appropriateness of such research designs.

Conclusions:

  • Well-designed placebo-controlled research is crucial for advancing treatment options for childhood schizophrenia.
  • This research will facilitate access to novel medications and ensure optimal drug therapy for children.
Abstract

Related Concept Videos